HR+/HER2- ADVANCED BREAST CANCER
Clinical trials for HR+/HER2- ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill combo aims to control advanced breast cancer
Disease control OngoingThis early-stage study tests a new oral drug (SH3765) combined with fulvestrant in 30 women with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy. The main goals are to find a safe dose and check for side effects, while also measurin…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Phase: PHASE1 • Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:38 UTC
-
Real-World data on breast cancer drug in elderly patients
Knowledge-focused OngoingThis study looks at how well a combination of ribociclib and hormone therapy works in patients aged 65 and older with a certain type of advanced breast cancer (HR+/HER2-). The goal is to measure changes in quality of life and how long the treatment remains effective. About 329 pa…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 26, 2026 08:57 UTC
-
Researchers to watch how breast cancer drugs work in everyday care
Knowledge-focused TerminatedThis study aimed to collect information from routine medical care for people with a certain type of advanced breast cancer (HR+/HER2-). Researchers planned to track side effects and how well treatments worked, without giving any new drugs. The study was withdrawn before enrolling…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Sponsor: SciClone Pharmaceuticals • Aim: Knowledge-focused
Last updated May 26, 2026 08:34 UTC
-
Real-World study tracks ribociclib combo for advanced breast cancer
Knowledge-focused OngoingThis study follows 376 people with HR+HER2- advanced breast cancer in Russia to see how well ribociclib combined with hormone therapy or chemotherapy works in routine medical practice. It does not assign treatments or visits—just observes what happens. The main goal is to measure…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 22, 2026 13:53 UTC